Cisplatin

  1. PATRICK J. LOEHRER, M.D.; and
  2. LAWRENCE H. EINHORN, M.D.
  1. Indianapolis, Indiana

    Abstract

    Cisplatin is a metal coordination compound that was approved for clinical use in treating testicular cancer 5 years ago. Although early trials showed marked gastrointestinal and renal toxicities, treatment-related morbidity has been significantly alleviated with modern antiemetic therapy and adequate pretreatment hydration. More recent clinical studies of cisplatin have shown a broad range of activity and provide a better understanding of the drug's pharmacology, mechanism of action, and toxicity. Variations in the dosage and mode of administration as well as development of cisplatin analogues are being currently studied.

    Article and Author Information

    • ▸From the Department of Medicine, Indiana University Medical Center, Indiana University; Indianapolis, Indiana.

    • Grant support: in part by grant MO1 RROO 750-06 from the Public Health Service, and grant CA-19657 from the Southeastern Cancer Study Group.

    • ▸Requests for reprints should be addressed to Patrick J. Loehrer, M.D.; Indiana University School of Medicine, Department of Medicine, Section of Hematology/Oncology, 926 West Michigan, Room N582; Indianapolis, IN 46223.

    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med May 1, 1984 vol. 100 no. 5 704-713
    1. » Abstract
    2. Full Text (PDF)

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. November 3, 2009, 151 (9)
    1. Alert me to current issues